Nektar Therapeutics (NKTR) was among the biggest gainers on the Russell 2000 for Thursday January 14 as the stock popped 5.23% to $13.88, representing a gain of $0.69 per share. Some 1.47 million shares traded hands on 10,971 trades, compared with an average daily volume of 1.49 million shares out of a total float of 133.45 million. The stock opened at $13.26 and traded with an intraday range of $13.94 to $12.79.
After today's gains, Nektar Therapeutics reached a market cap of $1.85 billion. Nektar Therapeutics has had a trading range between $17.55 and $9.16 over the last year, and it had a 50-day SMA of $15.03 and a 200-day SMA of $12.42.
Nektar Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops a pipeline of drug candidates that utilizes its PEGylation and polymer conjugate technology platforms that are designed to develop molecular entities.
Nektar Therapeutics is based out of San Francisco, CA and has some 438 employees. Its CEO is Howard W. Robin.
For a complete fundamental analysis analysis of Nektar Therapeutics, check out Equities.com’s Stock Valuation Analysis report for NKTR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer